Akari Therapeutics Plc (AKTX)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312016-Mar-312015-Dec-312015-Sep-302015-Jun-302015-Mar-312014-Dec-31
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014
Operating Cash Flow(3,041,000$)(2,121,000$)(3,256,000$)(2,150,000$)(2,124,000$)(1,490,000$)(4,894,000$)(4,044,000$)(4,409,000$)(2,449,000$)(4,694,000$)(4,880,000$)(7,440,576$)(6,770,475$)5,302,892$(1,298,000$)(1,988,478$)(667,978$)3,567,154$(2,328,000$)
Investing Cash Flow(42,083$)(18,779$)1,410,577$0$0$0$142,000$(142,000$)
Purchases of Property and Equipment42,083$0$
Financing Cash Flow5,760,000$1,897,000$3,381,000$2,133,000$2,154,000$(443,000$)7,763,000$1,514,000$3,517,000$0$291,000$3,212,000$(3,059,930$)72,104,349$0$0$3,893,191$(7,876,815$)0$
End Cash Position5,263,000$2,544,000$2,711,000$2,582,000$2,599,000$2,246,000$4,177,000$1,310,000$3,845,000$4,731,000$7,181,000$11,582,000$13,250,000$9,361,000$61,429,511$68,919,995$78,772,888$2,718,000$1,328,662$3,327,468$52,614$11,358,000$
Exchange Rate Effect0$(3,000$)1,000$2,000$(2,000$)(5,000$)6,000$(1,000$)
Dividends Paid
Unlevered Free Cash Flow(3,041,000$)(2,121,000$)(3,256,000$)(2,150,000$)(2,124,000$)(1,490,000$)(4,894,000$)(4,044,000$)(4,409,000$)(2,449,000$)(4,694,000$)(4,880,000$)(7,482,659$)(6,770,475$)5,302,892$(1,298,000$)(1,988,478$)(667,978$)3,567,154$(2,328,000$)